BeOne Medicines AG
BeOne Medicines AG Fundamental Analysis
BeOne Medicines AG (6160.HK) shows weak financial fundamentals with a PE ratio of 118.44, profit margin of 5.37%, and ROE of 7.28%. The company generates $5.6B in annual revenue with strong year-over-year growth of 54.96%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 6160.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6160.HK struggles to generate sufficient returns from assets.
Valuation Score
Weak6160.HK trades at a premium to fair value.
Growth Score
Excellent6160.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent6160.HK maintains a strong and stable balance sheet.
Profitability Score
Weak6160.HK struggles to sustain strong margins.
Key Financial Metrics
Is 6160.HK Expensive or Cheap?
P/E Ratio
6160.HK trades at 118.44 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 6160.HK's PEG of 2.87 indicates potential overvaluation.
Price to Book
The market values BeOne Medicines AG at 7.79 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 66.18 times EBITDA. This signals the market has high growth expectations.
How Well Does 6160.HK Make Money?
Net Profit Margin
For every $100 in sales, BeOne Medicines AG keeps $5.37 as profit after all expenses.
Operating Margin
Core operations generate 8.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.28 in profit for every $100 of shareholder equity.
ROA
BeOne Medicines AG generates $3.49 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BeOne Medicines AG produces operating cash flow of $1.18B, showing steady but balanced cash generation.
Free Cash Flow
BeOne Medicines AG generates strong free cash flow of $903.27M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.60 in free cash annually.
FCF Yield
6160.HK converts 2.44% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
118.44
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.87
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.79
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.64
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.41
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How 6160.HK Stacks Against Its Sector Peers
| Metric | 6160.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 118.44 | 28.31 | Worse (Expensive) |
| ROE | 7.28% | 699.00% | Weak |
| Net Margin | 5.37% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.25 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 3.41 | 2775.16 | Strong Liquidity |
| ROA | 3.49% | -14469.00% (disorted) | Weak |
6160.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BeOne Medicines AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
407.52%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
61.31%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
89.31%
Industry Style: Defensive, Growth, Innovation
High Growth